This is welcome news in a time of considerable turmoil both in the pharma and biotech sectors. There has been considerable consolidation in the former and numerous corporate failures in the latter. Another correlation that might be drawn is to the CEOs and staff of both of these two companies. Hard work, fortified by extreme dedication to the noble cause of biomedical product development and commercialization I consider the prime driver behind the recent Neuraxon and Transition Therapeutics successes. Is there a correlation that both companies are MaRS tenants? Yes. A stable workplace that includes proper infrastructure support provides any young discovery company with the acceleration it needs to travel along the sometimes lengthy road to profitability. Loss of R&D or production facilities can severely curtail or even terminate a company’s growth. If MaRS is to become the catalyst of future corporate successes it will need to continue to provide high quality facilities and services that suitably address the diverse needs of its various tenants. Most importantly, MaRS will have to accomplish this formidable task in an atmosphere where corporate entities are as diverse in size and financing as their commercial missions.